Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Todd Brady - President & Chief Executive Officer Joshua Reed - Chief Financial Officer David McMullin - Chief Commercial Officer Conference Call Participants Louise Chen - Cantor Yigal Nochomovit - Citi Group Adam Walsh - Stifel Esther Hong - Janney I-Eh Jen - Laidlaw Matthew Cross - Jones Trading Operator Good morning and to welcome to the Aldeyra Therapeutics Full Year 2019 Financial Re ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q3 2019 Results Conference Call November 7, 2019 8:00 AM ET Company Participants Todd Brady - Chief Executive Officer Joshua Reed - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citi Investment Research Sudan Loganathan - Cantor Fitzgerald & Company Esther Hong - Janney Montgomery Scott Adam Walsh - Stifel, Nicolaus & Company Matthew Cross - JonesTrading Institutional Services Operator Good morning and to welcome to the Aldeyra Therapeutics ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other jur ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q2 2019 Earnings Conference Call August 8, 2019 8:00 AM ET Company Participants Joshua Reed - CFO Todd Brady - CEO, President & Director Conference Call Participants Victor Rusu - Citigroup Esther Hong - Janney Montgomery Scott I-Eh Jen - Laidlaw & Company Matthew Cross - JonesTrading Institutional Services Operator Good morning. My name is Carol, and I will be your operator today. At this time, I would like to welcome everyone to the Aldeyra Therapeutics reports sec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other ju ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Todd Brady - Chief Executive Officer Joshua Reed - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Neil Carnahan - Stifel Financial Corp Esther Hong - Janney Montgomery Scott Matthew Cross - JonesTrading Operator Good morning and welcome to the Aldeyra Therapeutics First Quarter 2019 Financial Results and Corporate Update Conference Call. All participants w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2018 Results Earnings Conference Call March 8, 2019 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Todd Brady - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Esther Hong - Janney Montgomery Scott I-Eh Jen - Laidlaw & Company Matthew Cross - JonesTrading Operator Good morning and welcome to Aldeyra Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. All ...